Barry Kenny PhD
Barry Kenny joined the Metrion Biosciences Board of Directors in March 2018 and is currently Chief Business Officer of Heptares Therapeutics Ltd, now part of Sosei Group. He was previously Vice President, Drug Discovery at Takeda Cambridge, and Commercial Director at Paradigm Therapeutics.
Dr Kenny co-founded Cambridge Drug Discovery (CDD) in 1997, and was Director of Business Development for BioFocus following its merger with CDD in 2001.
Before this, Barry was at Pfizer Central Research, and spent eight years at Syntex Research Scotland, where he completed his PhD and post-doctoral studies.
Let’s work together
What are your specific ion channel and assay needs?
If you have any questions or would like to discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.